International Medical Journal, Vol. 26., Iss. 2, 2020, P. 11−15.
APPROACHES TO COMBINED TREATMENT OF PATIENTS WITH CARDIOPULMONARY PATHOLOGY
Kharkiv Medical Academy of Postgraduate Education
V. N. Karazin Kharkiv National University, Ukraine
Treatment and control of hypertension is an important clinical problem, especially in the case of concomitant risk factors and bronchoobstructive diseases. The use of antihypertensive drugs in the patients with bronchoobstructive pathology has certain features. The use of β−blockers for the treatment of hypertension in the patients with cardiopulmonary pathology helps to reduce mortality, the number of visits to the doctor, those to the emergency rooms and exacerbations of chronic obstructive pulmonary disease. Angiotensin II receptor antagonists are the preferred choice for the patients with chronic obstructive pulmonary disease, requiring the treatment with renin−angiotensin−aldosterone inhibitors compared with angiotensin−converting enzyme inhibitors. Statin therapy improves a shortness of breath, reduces exacerbations, hospitalizations and mortality in the patients with cardiopulmonary pathology. The use of anticoagulants and anti−platelet agents in this category of patients helps to reduce the future morbidity and mortality associated with thrombotic diseases. There are no safety concerns or contraindications to the use of calcium channel blockers or aldosterone receptor blockers (including spironolactone) in the patients with cardiopulmonary pathology, but high doses of diuretics should be used with caution. Pulmonary rehabilitation programs, which included either strength training or a combination of general exercise, were effective for both the patients with bronchoobstructive disease and comorbid conditions. However, the indications, components, regimen, and end goals of such programs for "complex patients" with several comorbid conditions that complicate each other are remained poorly understood.
Key words: cardiopulmonary comorbidity, drug treatment, physical rehabilitation, hypertension, chronic obstructive pulmonary disease.
1. Projections of mortality and causes of death, 2015 and 2030. (2018, November 12). URL: https://www. who.int/healthinfo/global_burden_disease/projections2015_2030/en/
2. The Global Impact of Respiratory Disease − Second Edition. (2018, October 23). URL: https://www.mdedge.com/chestphysician/article/140055/society−news/ global−impact−respiratory−disease−second−edition
3. Non communicable diseases. (n. d.). URL: https:// www.who.int/en/news−room/fact−sheets/detail/noncommunicable−diseases
4. Characteristics and prevalence of asthma/chronic obstructive pulmonary disease overlap in the United States / S. Kumbhare, R. Pleasants, J. A. Ohar, C. Strange // Ann. Am. Thorac. Soc. 2016. Vol. 13 (6). P. 803−810. doi: https://doi.org/10.1513/annalsats.201508−554oc
5. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990−2017: a systematic analysis for the global burden of disease study 2017 / S. L. James et al. // Lancet. 2018. Vol. 392 (10159). P. 1789−1858. doi: https://doi.org/10.1016/ S0140−6736(18)32279−7
6. Association of asthma−chronic obstructive pulmonary disease overlap syndrome with coronary artery disease, cardiac dysrhythmia and heart failure: a populationbased retrospective cohort study / J.−J. Yeh, Y.−F. Wei, C.−L. Lin, W.−H. Hsu // BMJ Open. 2017. Vol. 7 (10). doi: https://doi.org/10.1136/bmjopen−2017−017657corr1
7. Blood pressure increase between 55 and 68 years of age is inversely related to lung function: longitudinal results from the cohort study "Men born in 1914." / G. Engström et al. // J. of Hypertension. 2001. Vol. 19 (7). P. 1203−1208. doi: https://doi.org/10.1097/00004872−200107000−00004
8. Finkelstein J., Cha E., Scharf S. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity // International J. of Chronic Obstructive Pulmonary Disease. 2009. Vol. 337. doi: https://doi.org/10.2147/copd.s6400
9. Falola. Chronic obstructive pulmonary disease as a cardiovascular risk factor: results of a case−control study (CONSISTE study) // International J. of Chronic Obstructive Pulmonary Disease. 2013. Vol. 105. doi: https://doi.org/10.2147/copd.s40706
10. Concurrent physician−diagnosed asthma and chronic obstructive pulmonary disease: A population study of prevalence, incidence and mortality / T. Kendzerska et al. // Plos One. 2017. Vol. 12 (3). doi: https://doi.org/10.1371/journal.pone.0173830
11. Attitudes and preferences for the clinical management of patients with hypertension and hypertension with chronic obstructive pulmonary disease in Italy: main results of a survey questionnaire / G. Tocci et al. // Internal and Emergency Medicine. 2015. Vol. 10 (8). P. 943−954. doi: https://doi.org/10.1007/s11739−015−1256−y
12. Treatment of hypertension: The ESH/ESC guidelines recommendations / C. Cuspidi, M. Tadic, G. Grassi, G. Mancia // Pharmacological research. 2018. Vol. 128. P. 315−321. doi: https://doi.org/10.1016/j.phrs.2017.10.003
13. Di Daniele N. Therapeutic approaches of uncomplicated arterial hypertension in patients with COPD // Pulmonary pharmacology & therapeutics. 2015. Vol. 35. P. 1−7. doi: https://doi.org/10.1016/j.pupt.2015.09.004
14. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC / P. Ponikowski et al. // European Heart J. 2016. Vol. 37 (27). P. 2129−2200. doi: https://doi.org/10.1093/ eurheartj/ehw128
15. Banach M., Aronow W., Chandy D. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease // Integrated Blood Pressure Control. 2013. Vol 101. doi: https://doi.org/10.2147/ibpc.s33982
16. Global strategy for diagnosis, management, and prevention of COPD: The Global Initiative for Chronic Obstructive Lung Disease (GOLD). URL: http://www. goldcopd.com.
17. 116 Global strategy for asthma management and prevention, global initiative for asthma (GINA). URL: http:// www.ginasthma.org.
18. Renin−angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease / D. Shrikrishna, R. Astin, P. R. Kemp, N. S. Hopkinson // Clinical Science. 2012. Vol. 123 (8). P. 487−498. doi: https://doi.org/10.1042/cs20120081
19. Comparative effects of angiotensin−converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD / C.−C. Lai et al. // International J. of Chronic Obstructive Pulmonary Disease. 2018. Vol. 13. P. 867−874. doi: https://doi.org/10.2147/copd.s158634
20. Kim M. J., Im D. S. Suppressive effects of type I angiotensin receptor antagonists, candesartan and irbesartan on allergic asthma // European J. of pharmacology. 2019. Vol. 852. P. 25−33. doi: https://doi.org/10.1016/j.ejphar.2019.02.035
21. Geffen W. V., Kerstjens H. Static and dynamic hyperinflation during severe acute exacerbations of chronic obstructive pulmonary disease // International J. of Chronic Obstructive Pulmonary Disease. 2018. Vol. 13. P. 1269−1277. doi: https://doi.org/10.2147/copd.s154878
22. Statin use and risk of COPD exacerbation requiring hospitalization / M. T. Wang et al. // The American journal of medicine. 2013. Vol. 126 (7). P. 598−606. e2. doi: https://doi.org/10.1016/j.amjmed.2013.01.036
23. Increased Dose and Duration of Statin Use Is Associated with Decreased Asthma−Related Emergency Department Visits and Hospitalizations / J. Y. Wang et al. // The J. of allergy and clinical immunology. In practice. 2018. Vol. 6 (5). P. 1588−1595. doi: https://doi.org/10.1016/j.jaip.2017.12.017
24. COPD and risk of venous thromboembolism and mortality in a general population / T. Børvik et al. // European Respiratory J. 2015. Vol. 47 (2). P. 473−481. doi: 10.1183/13993003.00402−2015
25. Ekström M. P., Hermansson A. B., Ström K. E. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease // American J. of respiratory and critical care medicine. 2013. Vol. 187 (7). P. 715−720. doi: https://doi.org/10.1164/rccm.201208−1565oc
26. Kennedy J. L., Stoner A. N., Borish L. Aspirin−exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future // American J. of rhinology & allergy. 2016. Vol. 30 (6). P. 407−413. doi: https://doi.org/10.2500/ajra.2016.30.4370
27. Combination Antihypertensive Therapy Among Patients With COPD / M. A. Herrin et al. // Chest. 2013. Vol. 143 (5). P. 1312−1320. doi: https://doi.org/10.1378/chest.12−1770
28. Calcium channel blocker reduces airway remodeling in severe asthma. A proof−of−concept study / P. O. Girodet et al. // American J. of respiratory and critical care medicine. 2015. Vol. 191 (8). P. 876−883. doi: https://doi.org/10.1164/rccm.201410−1874oc
29. Nici L., ZuWallack R. Pulmonary Rehabilitation for Patients with Chronic Airways Obstruction // The J. of allergy and clinical immunology. In practice. 2015. Vol. 3 (4). P. 512−518. doi: https://doi.org/10.1016/j.jaip.2015.05.023
30. Ciolac E. G. Exercise training as a preventive tool for age−related disorders: a brief review // Clinics (Sao Paulo, Brazil). 2013. Vol. 68 (5). P. 710−717. doi: https://doi.org/10.6061/clinics/2013(05)20
31. The influence of comorbidities on outcomes of pulmonary rehabilitation programs in patients with COPD: a systematic review / M. Hornikx et al. // BioMed research international. 2013. P. 146−148. doi: https:// doi.org/10.1155/2013/146148